A simple and sensitive assay method for a pharmacokinetic study of Menaquinone-4 in dogs was established using HPLC with fluorescence detection following extraction with organic solvent. The quantification limit of this method was 1ng/ml of plasma. A new oily solution formulation of Menaquinone-4 was administered orally to non fasted dogs at doses of 0.4, 4 and 40mg/kg. The plasma concentrations reached maximum levels at 1 to 1.5h after dosing, and then decreased slowly. AUC values up to 24h after administration were almost dose proportional. Menaquinone-4 was also administered to dogs in soft capsules, for comparison with a conventional hard-capsule oral formula tion and an intravenous lecithin formulation. The mean AUC for oral dosing in the soft-capsule formulation was 13.5% of that for intravenous dosing in lecithin, and was 4.6 times higher than that for oral dosing in hard-capsules. Additional dosing in fasted dogs indicated that the AUC in pre-fed dogs was about 4 times higher, suggesting that feeding before giving Menaquinone-4 raises the bioavailability. Overall Menaquinone-4 was absorbed rapidly after administration in non-fasted dogs and dose proportional bioavailability was obtained among the doses of 0.4 to 40 mg/kg. Higher plasma concentrations were observed after administration in the soft-capsule formulation rather than in the hard-capsule formula tion. These findings suggest that the soft-capsule formulation would show a good pharmacokinetic profile for elderly patients with osteoporosis .
Summary
A simple and sensitive assay method for a pharmacokinetic study of Menaquinone-4 in dogs was established using HPLC with fluorescence detection following extraction with organic solvent. The quantification limit of this method was 1ng/ml of plasma. A new oily solution formulation of Menaquinone-4 was administered orally to non fasted dogs at doses of 0.4, 4 and 40mg/kg. The plasma concentrations reached maximum levels at 1 to 1.5h after dosing, and then decreased slowly. AUC values up to 24h after administration were almost dose proportional. Menaquinone-4 was also administered to dogs in soft capsules, for comparison with a conventional hard-capsule oral formula tion and an intravenous lecithin formulation. The mean AUC for oral dosing in the soft-capsule formulation was 13.5% of that for intravenous dosing in lecithin, and was 4.6 times higher than that for oral dosing in hard-capsules. Additional dosing in fasted dogs indicated that the AUC in pre-fed dogs was about 4 times higher, suggesting that feeding before giving Menaquinone-4 raises the bioavailability. Overall Menaquinone-4 was absorbed rapidly after administration in non-fasted dogs and dose proportional bioavailability was obtained among the doses of 0.4 to 40 mg/kg. Higher plasma concentrations were observed after administration in the soft-capsule formulation rather than in the hard-capsule formula tion. These findings suggest that the soft-capsule formulation would show a good pharmacokinetic profile for elderly patients with osteoporosis . Key Words Menaquinone-4, vitamin K, pharmacokinetics, dogs, oral, bioavailability, fluorescence detection, osteoporosis Menaquinone-4 (vitamin K2) is a potent coagulation cofactor even compared with Phylloquinone (vitamin K1), for hemorrhagic diseases , which is now being developed as a prophylaxis for osteoporosis (10) . In addition to the conventional hard-capsule formulation a more condensed formulation was required to improve compliance for elderly patients. A soft-capsule formulation , consisting of Mena quinone-4 in some fatty acid esters was developed in order to reduce the capsule size and to increase the absorption rate relative to the hard-capsule formulation . The relative and absolute bioavailability of those formulations were to be evaluated in dogs. However, the pharmacokinetic profile of Menaquinone-4 has not been investigated in dogs until now, although those in rodents were reported previously (11) (12) (13) (14) . Additionally, an improvement of the assay for Menaquinone-4 was required for these studies in dogs, because previous methods needed large volumes of plasma and/or complicated pre-treatment such as several steps of chromatogra phy (15) (16) (17) (18) (19) (20) .
In this report, we describe a simple and sensitive assay method for measure ment of Menaquinone-4 in plasma, and its use to determine the pharmacokinetic profile in dogs after oral administration of the soft-capsule formulation of Mena quinone-4.
MATERIALS AND METHODS
Materials. Menaquinone-4 and Menaquinone-6 were synthesized by Eisai Co., Ltd. (Tokyo, Japan). Propyleneglycol dicaprylate (Cefsol 228 _??_) and glycerol monooleate (MGOL-70_??_) were purchased from Nikko Chemicals Co ., Ltd. (Tokyo, Japan). Reagents for buffer solutions were of analytical grade and other solvents were of HPLC grade purchased from Wako Pure Chemical Industries , Ltd. (Osaka, Japan).
Animals. Beagle dogs (29-31 month age, 10-14kg) were obtained from Toyo Research Animal Inc. (Shizuoka, Japan). Animals were separately housed in stainless cages and fed 220g of food (DS, Oriental Yeast Co ., Ltd.) daily and water ad libitum. Before each administration of the test compound , dogs were fasted for more than 12h and then fed 1 h before dosing, except for animals used to evaluate the absorption under fasting conditions, which were not fed unitil 8h postdose .
Formulation. Two new and essentially identical formulations (one prepared in a soft-capsule and the other prepared as a oily solution) , and two commercially available formulations (a hard-capsule for oral use and an injectable lecithin formulation) were used in this study. The two new formulations and the hard capsule formulation were administered orally, while intravenous administration was performed with the lecithin preparation. These formulations are summarized below. a) New formulations: Type 1 (oily solution, SC 1): Menaquinone-4 was dissolved in Cefsol 228/MGOL-70 (40:55) at concentrations of 0 .4, 4, and 40mg/ 80mg. The solution was administered in a gelatin capsule. Calculation of pharmacokinetic parameters. Pharmacokinetic parameters in this study were calculated by model independent methods, except for those in the intravenous injection study, as follows.
Cmax and Tmax for oral doses were determined directly from the measured concentrations. AUC was calculated by the trapezoidal method using plasma concentrations up to 10h (AUC(0-10h)) and 24h (AUC(0-24h)) after dosing. Concentrations below the limit of quantification were treated as zero for the caluculation of AUC. Bioavailability was estimated by comparing the AUCs for the oral and intravenous doses.
Half-life for intravenous injection was obtained from the plasma concentra tions up to 6h after dosing, using a nonlinear least-squares method (21) .
RESULTS

Extraction and separation on HPLC
Various organic solvents were evaluated to optimize the extraction of Mena quinone-4 from dog plasma. Although only about half the added Menaquinone-4 was recovered using n-hexane (conventional extraction solvent for vitamin K families), two extractions with isopropyl alcohol/n-hexane (8:92) from buffered plasma (pH 8.0) gave a quantitative recovery (more than 90% for both Menaqui none-4 and Menaquinone-6), with no interfering peak on the HPLC chromato grams. Additional separation of Menaquinone-4 from endogenous compounds was achieved by using EtOH/MeOH/H2O (50:47:3) as a mobile phase for the fluores cence detection. For UV detection, the use of 0.1M Tris buffer (pH 8.0) instead of H2O in the mobile phase was better for separating Menaquinone-4 from interfering peaks. The overall procedure is shown in Fig. 1 Dose-relationship of the plasma concentration The concentrations of Menaquinone-4 in dog plasma after oral administration of the SC1 formulation at doses of 0.4, 4, and 40mg/kg are shown in Fig. 3 . The pharmacokinetic parameters, calculated by model independent analysis, are shown non-fasted animals.
were observed: a) rapid absorption type showing T max at 1 to 3h, b) slow absorption type with Tmax of 8 to 10h, c) long-term absorption type . As a consequence, the mean AUC up to 10h was 13.5% of that for intravenous administration of LF . Lower concentrations after oral administration of HC were observed relative to those of SC2. The time-concentration profile was, however , similar to that of SC 2 showing both rapid and late absorption patterns . The mean AUC of SC2 was 4.6 times higher than that of HC, indicating that the bioavailability of Menaquinone-4 after dosing of SC2 was higher.
Effect of feeding on bioavailability
In all the experiments above, an appropriate amount of food was given to aminals prior to dosing. To evaluate the effect of feeding on absorption , Menaqui none-4 (SC2) was administered to dogs that had been fasted for more than 12h . The pharmacokinetic parameters for fasted and non-fasted dogs are shown in Table  3 . Only rapid absorption was observed in the fasted dogs , with Tmax at 2h after dosing. Concentrations of Menaquinone-4 were, however , reduced markedly at each time point, and the Cmax and AUC for the fasted dogs were 5 .2 and 3.9 times lower than those for the pre-fed animals. These results suggest that feeding prior to dosing facilitates the intestinal absorptiuon of Menaquinone-4 in dogs . DISCUSSION A sensitive assay method to measure Menaquinone-4 in dog plasma was established and used for a characterization of pharmacokinetics in dogs .
Until now several methods to measure vitamin K families in plasma have been reported using HPLC with fluorescence detection following reduction of quinone moiety to corresponding hydroquinones (15) (16) (17) (18) (19) (20) . Most of these methods , however, require large volumes of plasma and/or complicated pre-treatments to obtain high sensitivity. Therefore only limited number of samples could be collected , so the time-concentration profiles of vitamin K could not be fully defined . Recently, Shino improved the previous methods in which the reduction was performed conveniently with H2 gas saturated mobile phase and a reduction column , and plasma concentrations of vitamin K families in several species including humans were measured (20 that of HC. These findings suggested that the bioavailability of Menaquinone-4 following oral dosing of SC was superior to that of HC in dogs . In fasted dogs, only the rapid absorption was seen in all animals , and time-concentration profiles showed a simple pattern. However , the Cmax and AUC values were markedly lower than those in non-fasted dogs . As previous studies have demonstrated that the bile is required for the efficient absorption of Phyllo quinone (3-5), it can be supposed that the small amount of bile limited the absorption of Menaquinone-4 in fasted dogs . Consequently, oral administration after feeding is recommended to raise the bioavailability of Menaquinone-4 .
In conclusion, the development of an improved assay method for Menaqui none-4 has enabled us to study the pharmacokinetics of the drug in dogs . Menaqui none-4 was absorbed rapidly after oral administration in oily solution . Feeding the dogs prior to dosing raised the bioavailability, and the dose-proportional bio availability was observed with the dose-range of 0 .4 to 40mg/kg. The plasma concentrations were also higher after administration of the soft-capsule formula tion, rather than the conventional hard-capsule formulation . These findings suggest that the soft-capsule formulation would show a good pharmacokinetic profile for elderly patients with osteoporosis. 
